Doramapimod, p38 MAP kinase inhibitor
Stock availabilitIn Stock
p38 MAP kinase inhibitor
Primary research fields
Cell Signaling, Cancer, Apoptosis, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors
JNK Inhibitor XVII, BIRB796, 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
Soluble in DMSO
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
Doramapimod is a highly potent and selective inhibitor of p38α MAPK. It specifically blocks TNFα release.
1. Pargellis C., et al. (2002). Nat Structural Biol. 9(4): 268–272.
Refer to PubMed
To be tested
To be tested
Representative figure legend
Chemical structure of Doramapimod (SIH-442), a p38 MAP kinase inhibitor. CAS #: 285983-48-4. Molecular Formula: C31H37N5O3. Molecular Weight: 527.7 g/mol. Chemical structure of Doramapimod, a p38 MAP kinase inhibitor (SIH-442). CAS # 285983-48-4. Molecular Formula: C31H37N5O3.
Country of production
Total weight (kg)
Net weight (g)
Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.